NCT04906798Unknown1 期
A Randomized, Open-label, Single Dose, Crossover Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-385 High-dose in Healthy Volunteers Under Fasting Conditions
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 入组人数
- 52
- 试验地点
- 1
- 主要终点
- AUCt of CKD-385
研究概览
简要总结
Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of Highdose CKD-385 in Healthy Volunteers under Fasting Conditions
详细描述
A randomized, open-label, single dose, crossover study to evaluate the pharmacokinetic profiles and safety of CKD-385 high-dose in healthy volunteers under fasting conditions
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 54 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adults age≥19 years and age<55 years at the time of screening
- •Individuals who had 17.5 kg/m2 ≤ Body Mass Index(BMI) < 30.5kg/m2 and men's total body weight ≥ 55 kg, women's total body weight ≥ 45 kg
- •* BMI = Weight(kg)/ Height(m)2
- •Individuals without congenital/chronic diseases and without abnormal symptoms or diagnosis based on a medical examination within the last 3 years
- •Individuals who were deemed to be appropriate as study subjects following laboratory tests (hematology, blood chemistry, urinalysis, viral/ bacterial, etc.) and vital signs, ECG etc. performed at screening
- •Individuals who signed an informed consent form approved by the IRB of Chonbuk National University Hospital and decided to participate in the study after being fully informed of the study prior to participation, including the objective, content and characteristics of the investigational product
- •Individuals who agreed proper contraception during the study and did consent to not donation of sperm 1 month after the last dose of study drug infusion
- •Individuals with the ability and willingness to participate the entire study period
排除标准
- •Subject who has (or has histories of) clinically significant blood, kidney, endocrine, respiratory, gastrointestinal, urinary, cardiovascular, liver, mental, neurological or allergic diseases(except for asymptomatic seasonal allergy at the time of administration) or evidence(except for simple dental history such as dental calculus, impacted tooth, wisdom tooth, etc.)
- •Subject with a history of gastrointestinal disorders(esophageal achalasia or esophagus stenosis, Crohn's disease) or gastrointestinal surgery(except for simple appendicitis surgery or hernia surgery or tooth extraction surgery) that may affect the absorption of drug
- •Subject who shows the following values as a result of laboratory tests
- •*ALT or AST > 2 times upper limit of normal range
- •Subject who has a history of regular alcohol consumption in excess of 210 g/week within 6 months of screening
- •Subject who smokes more than one pack of cigarette a day within 6 months of screening
- •Subject who took other clinical trial drugs or bioequivalence test drugs within 3 months before the first administration of clinical trial drug
- •Subject who conform to the specific items below
- •systolic blood pressure less than 90 mmHg, greater than 140 mmHg or diastolic blood pressure less than 60 mmHg or greater than 90 mmHg in a sitting position
- •Severe bradycardia (less than 50 beats/minute)
- •Subject who has significant alcohol abuse or drug abuse within a year of screening
- •Subject who took drugs which are known as disturbing drug metabolism within 30 days prior to the first administration of clinical trial drug.
- •Subject who uses any of other drugs, including over-the-counter medications and prescription medications within 10 days prior to first administration of clinical trial drug.
- •Subject who donated whole blood within 2 months prior to first administration of clinical trial drug or blood components within 1 month prior to first administration of clinical trial drug
- •Subject who is hypersensitive to the components of a clinical trial drug or clinical trial drug itself.
- •Subject had genetic dysfunctions like galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption
- •Subjects who were deemed inappropriate to participate in the study by the investigator
研究组 & 干预措施
Sequence1
Experimental
- Period 1: Reference drug(D744)
- Period 2: Test drug(CKD-385)
干预措施: D744 (Drug)
Sequence2
Experimental
- Period 1: Test drug(CKD-385)
- Period 2: Reference drug(D744)
干预措施: CKD-385 (Drug)
Sequence1
Experimental
- Period 1: Reference drug(D744)
- Period 2: Test drug(CKD-385)
干预措施: CKD-385 (Drug)
Sequence2
Experimental
- Period 1: Test drug(CKD-385)
- Period 2: Reference drug(D744)
干预措施: D744 (Drug)
结局指标
主要结局
AUCt of CKD-385
时间窗: Pre-dose (0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48 hours
Area under the concentration-time curve from time zero to time of CKD-385
次要结局
- CL/F of CKD-385(Pre-dose (0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48 hours)
- T1/2 of CKD-385(Pre-dose (0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48 hours)
- Vd/F of CKD-385(Pre-dose (0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48 hours)
- AUCinf of CKD-385(Pre-dose (0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48 hours)
- Tmax of CKD-385(Pre-dose (0 hour), 0.17, 0.33, 0.5, 0.75, 1, 1.5, 2, 2.5, 3, 4, 5, 6, 8, 12, 24, 48 hours)
研究者
研究点 (1)
Loading locations...
相似试验
Unknown
1 期
Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fed ConditionsCardiovascular DiseasesNCT04651881Chong Kun Dang Pharmaceutical24
Unknown
1 期
Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fasting ConditionsCardiovascular DiseasesNCT04678388Chong Kun Dang Pharmaceutical24
Unknown
1 期
Clinical Study to Investigate the PK Profiles and Safety of CKD-385 in Healthy Volunteers Under Fed ConditionsCardiovascular DiseasesNCT04906785Chong Kun Dang Pharmaceutical52
已完成
1 期
A Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-393(2) in Healthy Volunteers Under Fed ConditionsType2DiabetesNCT05347576Chong Kun Dang Pharmaceutical31
已完成
1 期
A Clinical Trial to Evaluate the Tolerability and Pharmacokinetics of CKD-386(5) 80/20/10mgHypertension and DyslipidemiaNCT05698043Chong Kun Dang Pharmaceutical63